January 21, 2014 (Shareholders Foundation) - An investigation on behalf of current long-term stockholders of shares of Intercept Pharmaceuticals Inc (NASDAQ:ICPT) was announced concerning whether Intercept Pharmaceuticals officers and directors possibly breached their fiduciary duties in connection with certain statements.

The investigation by a law firm concerns whether certain Intercept Pharmaceuticals officers and directors breached their fiduciary duties

On January 9, 2014, Intercept Pharmaceuticals announced that the FLINT clinical trial study of obeticholic acid (OCA) was stopped early for efficacy after a planned interim analysis showed the primary endpoint had been met. OCA is being developed by Intercept for the treatment of nonalcoholic steatohepatitis. On this news announcement, shares of Intercept Pharmaceuticals increased over 500% over the next two trading sessions.

After the market close on Friday, January 10, 2014, The Wall Street Journal issued a report via a statement made by the National Institutes of Health stating that patients treated with Intercept's OCA in the clinical trial experienced 'lipid abnormalities,' higher levels of 'bad' LDL cholesterol and lowers levels of 'good' HDL cholesterol, compared to patients treated with placebo.

On Sunday, January 12, 2014, Intercept Pharmaceuticals made an announcement providing additional details of the OCA study including the lipid abnormalities disclosed in The Wall Street Journal report. In midday trading on Tuesday, January 14, 2014, the stock has traded down as much as $210.83 or 47% since the announcement made on Sunday.